Loading clinical trials...
Loading clinical trials...
AEE788 is an orally active, reversible, small-molecule, multi-targeted kinase inhibitor with potent inhibitory activity against ErbB and VEGF receptor family of tyrosine kinases. It has an IC50 of les...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT06312137 · Non Small Cell Lung Cancer
NCT07005128 · Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer
NCT06467357 · Biliary Tract Cancer
NCT07586215 · Breast Cancer Metastatic
NCT07489716 · Non-Small Cell Lung Cancer
Yale Cancer Center
New Haven, Connecticut
Nevada Cancer Institute
Las Vegas, Nevada
Sarah Cannon Research Institute
Nashville, Tennessee
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions